"It is one of the most common causes of hospitalization for infants under two years of life,"
"But infants can't do that," she said. "You can see it when they're trying to feed or they can't breathe because they have a stuffed up nose. They haven't yet learned to breathe through their mouth and nose at the same time, so they can't clear the virus from the bottom of their lungs. They can't cough it up."
"Last year, prenatal Abrysvo vaccinations, along with immunizations given to infants using the monoclonal antibody medication called nirsevimab, have resulted in an estimated 50% decline in the number of child hospitalizations at Kaiser Permanente hospitals in Northern California."
Kaiser Permanente is offering the single-dose maternal RSV vaccine Abrysvo to pregnant patients to help protect newborns against respiratory syncytial virus. RSV commonly causes mild symptoms in adults but can lead to severe lower respiratory tract infections in infants, who cannot effectively clear the virus and may struggle to breathe or feed. Federal data show 2–3 of every 100 babies under six months are hospitalized annually for RSV, and RSV is a leading cause of hospitalization for children under two. Prenatal Abrysvo plus infant nirsevimab immunizations coincided with an estimated 50% drop in child hospitalizations at Kaiser Northern California; more than 9,000 pregnant patients were vaccinated, a 67% increase from 2023. Current federal guidance does not recommend repeating the maternal vaccine in subsequent pregnancies if the mother already received it previously.
Read at The Mercury News
Unable to calculate read time
Collection
[
|
...
]